Fred R. Hirsch
Fred R. Hirsch, MD, PhD

Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute

Latest Stories

ClinicalTrials & Tribulations
FDA’s recent approval of an immunotherapy in the adjuvant setting for stage II-IIIA non-small cell lung cancer makes it all the more urgent to detect lung cancer at early stages.
ClinicalCOVID-19 & CancerTrials & Tribulations
Researchers from Icahn School of Medicine at Mount Sinai was recently awarded a U54 grant ($3.9 million over the first two years as a part of a five-year research proposal) to establish a NCI/SeroNet Center for Serological Excellence at Mount Sinai with a focus on lung cancer.
COVID-19 & CancerFreeGuest Editorial
The COVID-19 pandemic has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and health care providers.
ClinicalTrials & Tribulations
We were recently presented with the new report from American Cancer Society1 showing the biggest annual decrease in cancer mortality, which was mainly due to decline in smoking, as well as improvements in early detection and treatment.
ClinicalFreeTrials & Tribulations
Despite much progress in lung cancer over the last decade, lung cancer is the most frequent cause of cancer death.